$SpaceX(SPCX)$ SPCX looks like it's running into meaningful overhead supply in the $150 - $155 area, likely tied to prior support and people looking to get out at breakeven after the June breakdown. Still, the fact that positive momentum keeps hanging in there and the level keeps getting retested makes me think the market is gradually absorbing that supply rather than getting turned away hard. A sustained move or close above $155 would be a stronger signal that this resistance band has mostly been worked through.
$Dell Technologies Inc.(DELL)$ On the bright side, it still closed higher than the previous session even with SPY falling off a cliff. Insiders aren't going to sell twice. Still holding the 530s, so it's possible we get a more natural retest of highs going forward instead of a pump-and-dump type move like we just saw.
$Dell Technologies Inc.(DELL)$ Dell Technologies price target raised to $650 from $575 at Evercore ISI. Evercore ISI lifted its price target on Dell Technologies to $650 from $575 and kept an Outperform rating on the shares. The firm still sees room for further appreciation, with the next phase driven by enterprise AI adoption, higher margin attach, and continued operating expense leverage. The analyst also pointed to an upside EPS scenario where FY27 EPS approaches $30, compared with current Street estimates around $25.88 and the firm's base estimate of $25.54. At $40-plus of EPS and a 25-times forward P/E multiple, the firm sees a path toward $1,000 per share.
$SK hynix(SKHY)$ Ripped 20 points higher in a single session off that breakout call. Might cool off short term after a move like that, but I'm leaning toward more upside continuation from here.
$IREN Ltd(IREN)$ Max pain for this week is 38, so trade with that in mind. There was a big move today getting over the 38.54 fib level without much trouble. Now the focus is on the open and whether price gets taken back under 38.54, which would turn that area into a battleground between support and resistance. If it holds cleanly above, 44.39 is the next level up, but looking at the clouds, momentum is questionable. The shorter time frames are stretched high, while the longer time frame is still under the red global, so there are likely more battles ahead. After hitting 35 twice last week or so, it looked like the market was saying enough is enough. Global politics are causing the dips and rips, but the good ne
$Moderna, Inc.(MRNA)$ The regulatory submission for the melanoma vaccine is getting close, possibly as early as next month. Data should be out soon, and approvals by early 2027 would set things up for a solid launch. Readouts from other cancer products could add more momentum for the oncology platform.